Satellos Reports Q2 2026 Loss of $11.7M, Cash Runway Through 2027, and Positive TRAILHEAD Data
MSLE sits 81% above its 52-week low of $5.44.
Summary
Satellos reported Q2 2026 results with a wider net loss but a strong cash position of $61.8M, and reiterated positive TRAILHEAD data and Q4 2026 BASECAMP data expectations.
Key Events · Earnings and Guidance · MSLE
-
Q2 Net Loss Widens
Net loss of $11.7M ($0.56/share) vs $5.6M ($0.39/share) in Q2 2025, driven by R&D expenses up 117% to $9.6M.
-
Cash Runway Through 2027
Cash, cash equivalents and short-term investments of $61.8M as of June 30, 2026, expected to fund operations through 2027.
-
TRAILHEAD Data Positive
Six-month data in four adults showed reduced muscle fat fraction, increased total effort, stable strength, and improved quality of life.
-
BASECAMP Data in Q4 2026
Phase 2 pediatric study actively enrolling; company expects to report clinical data in Q4 2026.
Analysis · MSLE · Life Sciences
Satellos Bioscience reported a wider Q2 net loss of $11.7 million as R&D spending nearly doubled to $9.6 million, driven by the BASECAMP and TRAILHEAD Phase 2 trials. The company holds $61.8 million in cash and short-term investments, which management says funds operations through 2027. The six-month TRAILHEAD data showed reduced muscle fat fraction and increased total effort in all four participants, suggesting muscle regeneration. BASECAMP enrollment is advancing with data expected in Q4 2026, and an IND for FSHD is planned for the second half of 2026. The financial position removes near-term financing risk, while the clinical updates keep the stock's value tied to upcoming data readouts.
At the time of this filing, MSLE was trading at $9.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $204.6M. The 52-week trading range was $5.44 to $144.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.